Upstream Bio Reports Q3 2026 Results, Plans Phase 3 Trials for 2027
Upstream Bio reported a Q3 2026 net loss of $41.2M, up from $33.7M a year earlier, with collaboration revenue of $395K. The company has $207.4M in cash, expecting to fund operations through 2027. Upstream Bio plans to start Phase 3 trials for verekitug in severe asthma and CRSwNP in Q1 2027, with additional trials in COPD and severe asthma expected to report data in 2027.
How this was made
The 30-second read
Why it matters
The earnings miss and increased R&D expense suggest short‑term pressure, but the upcoming Phase 3 trials could be a longer‑term catalyst.
Market read
Primary micro‑cap biotech earnings release with new trial plans; likely short‑term downside but potential long‑term upside.
What to watch
Collaboration revenue, though small, indicates partnership interest that could expand.
Background
Upstream Bio (NASDAQ:UPB) reported its Q3 2026 results, highlighting a larger net loss, modest collaboration revenue, and plans for Phase 3 trials of its TSLP‑targeting drug verekitug.
Ticker impact
Upstream Bio disclosed Q3 2026 net loss of $41.2M and plans Phase 3 trials in Q1 2027, new financial and clinical updates.
likely downside as market prices in higher loss and cash burn
Loss widened YoY, cash runway only to 2027, and no revenue growth beyond minimal collaboration revenue.
Market effects
Biotech sector may see heightened scrutiny on cash‑burn and trial timelines.
Limited to US‑listed biotech investors.
Minimal global impact beyond niche biotech community.
Counterpoint
Investors could view the cash runway to 2027 as a runway for a potential upside catalyst if Phase 3 data are positive.
Key entities
- companyUpstream Bio Inc.
Biotech firm developing verekitug for severe asthma, CRSwNP, and COPD.
